de Gauzy Jérôme Sales, Abid Abdelazis, Accadbled Franck, Knorr Gorka, Darodes Philippe, Cahuzac Jean Philippe
Department of Orthopaedic Pediatric Surgery, CHU, Toulouse, France.
J Pediatr Orthop B. 2005 Sep;14(5):367-70. doi: 10.1097/01202412-200509000-00010.
The effects of percutaneous Ethibloc (Ethicon/Johnson & Johnson, St-Stevens-Woluwe, Belgium) injection into primary aneurysmal bone cysts were analysed. Two patients with a venous drainage after injection of a medium contrast were excluded. Twelve patients underwent at least one percutaneous injection of Ethibloc. The average follow-up period was 5.1 years. At final follow-up, six patients had complete healing of the cyst, three had partial healing and three, who had no response, were treated by curettage and bone grafting. Complete healing was observed for all the aggressive lesions. No major complications were noted. Ethibloc injection may be performed as a primary treatment of aneurysmal bone cysts if the technique is followed with precision.
分析了经皮注射Ethibloc（Ethicon/强生公司，比利时圣斯特凡斯-沃卢韦）对原发性骨囊肿的疗效。两名在注射中等造影剂后出现静脉引流的患者被排除在外。12名患者接受了至少一次Ethibloc经皮注射。平均随访期为5.1年。在最后随访时，6名患者囊肿完全愈合，3名部分愈合，3名无反应的患者接受了刮除术和骨移植治疗。所有侵袭性病变均观察到完全愈合。未发现重大并发症。如果严格遵循该技术，Ethibloc注射可作为骨囊肿的主要治疗方法。
